[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100559771":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":34,"centralContacts":39,"locations":44,"responsibleParty":276,"collaborators":33,"id":278,"slug":279,"hasResults":280,"nctId":281,"briefTitle":282,"officialTitle":283,"acronym":33,"eligibilityCriteria":284,"healthyVolunteers":280,"sex":285,"minAge":286,"maxAge":33,"enrollmentInfo":287,"targetDuration":33,"studyType":290,"phases":291,"briefSummary":293,"conditions":294,"keywords":302,"overallStatus":47,"whyStopped":33,"lastUpdateSubmitDate":304,"lastUpdatePostDateStruct":305,"startDateStruct":308,"completionDateStruct":310,"leadSponsor":312,"locationsCount":313},{"fullName":5,"class":6},"Hasten Biopharmaceutical Co., Ltd.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"HST101(Lerodalcibep)","EXPERIMENTAL","300 mg subcutaneously Q4W",[13],"Drug: Lerodalcibep",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","subcutaneously Q4W",[19],"Drug: matching placebo",[21,29],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Lerodalcibep","PCSK9 inhibitor",[9],[27,28],"HST101","LIB003",{"type":22,"name":30,"description":31,"armGroupLabels":32,"otherNames":33},"matching placebo","placebo",[15],null,[35],{"name":36,"affiliation":37,"role":38},"Yong Huo","Peking University First Hospital","PRINCIPAL_INVESTIGATOR",[40],{"name":36,"role":41,"phone":42,"phoneExt":33,"email":43},"CONTACT","+86 13901333060","huoyong@263.net.cn",[45,63,73,83,93,107,121,135,149,159,173,187,200,213,226,240,254,268],{"facility":46,"status":47,"city":48,"state":49,"zip":33,"country":50,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":58},"Beijing Anzhen Hospital of Capital Medical University","RECRUITING","Beijing","Beijing Municipality","China","CN",{"type":53,"coordinates":54},"Point",[55,56],116.39723,39.9075,{"lat":56,"lon":55},[59],{"name":60,"role":41,"phone":61,"phoneExt":33,"email":62},"Yujie Zhou","+86-10-64412431","azzyj12@163.com",{"facility":64,"status":47,"city":48,"state":49,"zip":33,"country":50,"countryCode":51,"cosmosGeoPoint":65,"geoPoint":67,"contacts":68},"Beijing Luhe Hospital, Capital Medical Univeristy",{"type":53,"coordinates":66},[55,56],{"lat":56,"lon":55},[69],{"name":70,"role":41,"phone":71,"phoneExt":33,"email":72},"Guangyao Zhai","+86-10-69543901","Drzhaiguangyao@163.com",{"facility":74,"status":47,"city":48,"state":49,"zip":33,"country":50,"countryCode":51,"cosmosGeoPoint":75,"geoPoint":77,"contacts":78},"Beijing Tsinghua Changgeng Hospital",{"type":53,"coordinates":76},[55,56],{"lat":56,"lon":55},[79],{"name":80,"role":41,"phone":81,"phoneExt":33,"email":82},"Ping Zhang","+86-10-56112345","zhpdoc@126.com",{"facility":84,"status":47,"city":48,"state":49,"zip":33,"country":50,"countryCode":51,"cosmosGeoPoint":85,"geoPoint":87,"contacts":88},"Fuwai Hospital, CAMS & PUMC",{"type":53,"coordinates":86},[55,56],{"lat":56,"lon":55},[89],{"name":90,"role":41,"phone":91,"phoneExt":33,"email":92},"Naqiong Wu","+86-10-88398866","fuwainaqiongwu@163.com",{"facility":94,"status":47,"city":95,"state":96,"zip":33,"country":50,"countryCode":51,"cosmosGeoPoint":97,"geoPoint":101,"contacts":102},"Guangdong Provincial People's Hospital","Guangzhou","Guangdong",{"type":53,"coordinates":98},[99,100],113.25,23.11667,{"lat":100,"lon":99},[103],{"name":104,"role":41,"phone":105,"phoneExt":33,"email":106},"Ning Tan","+86-20-83827812","tanning100@126.com",{"facility":108,"status":47,"city":109,"state":110,"zip":33,"country":50,"countryCode":51,"cosmosGeoPoint":111,"geoPoint":115,"contacts":116},"Shijiazhuang People's Hospital","Shijiazhuang","Hebei",{"type":53,"coordinates":112},[113,114],114.47861,38.04139,{"lat":114,"lon":113},[117],{"name":118,"role":41,"phone":119,"phoneExt":33,"email":120},"Jianping Zhang","+86-311-69089999","zjpzjp2013@sina.com",{"facility":122,"status":47,"city":123,"state":124,"zip":33,"country":50,"countryCode":51,"cosmosGeoPoint":125,"geoPoint":129,"contacts":130},"Daqingshi People's Hospital","Daqing","Heilingjiang",{"type":53,"coordinates":126},[127,128],125,46.58333,{"lat":128,"lon":127},[131],{"name":132,"role":41,"phone":133,"phoneExt":33,"email":134},"Shu Zhang","+86-459-6612000","zhangshu7801182@163.com",{"facility":136,"status":47,"city":137,"state":138,"zip":33,"country":50,"countryCode":51,"cosmosGeoPoint":139,"geoPoint":143,"contacts":144},"The 2nd Xiangya Hospital of Central South University","Changsha","Hunan",{"type":53,"coordinates":140},[141,142],112.97087,28.19874,{"lat":142,"lon":141},[145],{"name":146,"role":41,"phone":147,"phoneExt":33,"email":148},"Daoquan Peng","+86-731-85295888","pengdq@hotmail.com",{"facility":150,"status":47,"city":137,"state":138,"zip":33,"country":50,"countryCode":51,"cosmosGeoPoint":151,"geoPoint":153,"contacts":154},"The Third Xiangya Hospital of Central South University",{"type":53,"coordinates":152},[141,142],{"lat":142,"lon":141},[155],{"name":156,"role":41,"phone":157,"phoneExt":33,"email":158},"Weihong Jiang","+86-731-88618576","jwhxy3@126.com",{"facility":160,"status":47,"city":161,"state":162,"zip":33,"country":50,"countryCode":51,"cosmosGeoPoint":163,"geoPoint":167,"contacts":168},"Nanchang People's Hospital","Nanchang","Jiangxi",{"type":53,"coordinates":164},[165,166],115.85306,28.68396,{"lat":166,"lon":165},[169],{"name":170,"role":41,"phone":171,"phoneExt":33,"email":172},"Zhaohui Pei","+86-791-86612623","Leak123@126.com",{"facility":174,"status":47,"city":175,"state":176,"zip":33,"country":50,"countryCode":51,"cosmosGeoPoint":177,"geoPoint":181,"contacts":182},"Binzhou Medical University Hospital","Binzhou","Shandong",{"type":53,"coordinates":178},[179,180],118.01667,37.36667,{"lat":180,"lon":179},[183],{"name":184,"role":41,"phone":185,"phoneExt":33,"email":186},"Huipu Xu","+86-543-3256969","xuhuipu@126.com",{"facility":188,"status":47,"city":189,"state":176,"zip":33,"country":50,"countryCode":51,"cosmosGeoPoint":190,"geoPoint":194,"contacts":195},"Heze Municipal Hospital","Heze",{"type":53,"coordinates":191},[192,193],115.47358,35.23929,{"lat":193,"lon":192},[196],{"name":197,"role":41,"phone":198,"phoneExt":33,"email":199},"Beijian Chen","+86-530-5613239","cbj9603@163.com",{"facility":201,"status":47,"city":202,"state":176,"zip":33,"country":50,"countryCode":51,"cosmosGeoPoint":203,"geoPoint":207,"contacts":208},"Qilu Hospital of Shandong University","Jinan",{"type":53,"coordinates":204},[205,206],116.99722,36.66833,{"lat":206,"lon":205},[209],{"name":210,"role":41,"phone":211,"phoneExt":33,"email":212},"Cheng Zhang","+86-531-82166666","zhangc@sdu.edu.cn",{"facility":214,"status":47,"city":215,"state":176,"zip":33,"country":50,"countryCode":51,"cosmosGeoPoint":216,"geoPoint":220,"contacts":221},"Zibo Municipal Hospital","Zibo",{"type":53,"coordinates":217},[218,219],118.06333,36.79056,{"lat":219,"lon":218},[222],{"name":223,"role":41,"phone":224,"phoneExt":33,"email":225},"Guanzhong Zheng","+86-533-7162009","m17660292598@163.com",{"facility":227,"status":47,"city":228,"state":229,"zip":33,"country":50,"countryCode":51,"cosmosGeoPoint":230,"geoPoint":234,"contacts":235},"West China Hospital of Sichuan University","Chengdu","Sichuan",{"type":53,"coordinates":231},[232,233],104.06667,30.66667,{"lat":233,"lon":232},[236],{"name":237,"role":41,"phone":238,"phoneExt":33,"email":239},"Ye Zhu","+86-28-85422114","zhuye1974@163.com",{"facility":241,"status":47,"city":242,"state":243,"zip":33,"country":50,"countryCode":51,"cosmosGeoPoint":244,"geoPoint":248,"contacts":249},"Tianjin People's Hospital","Tianjin","Tianjin Municipality",{"type":53,"coordinates":245},[246,247],117.17667,39.14222,{"lat":247,"lon":246},[250],{"name":251,"role":41,"phone":252,"phoneExt":33,"email":253},"Zhuhua Yao","+86-22-87729595","yzhpci@yahoo.com.cn",{"facility":255,"status":47,"city":256,"state":257,"zip":33,"country":50,"countryCode":51,"cosmosGeoPoint":258,"geoPoint":262,"contacts":263},"The First Affiliated Hospital of Wenzhou Medical Univesity","Wenzhou","Zhejiang",{"type":53,"coordinates":259},[260,261],120.66682,27.99942,{"lat":261,"lon":260},[264],{"name":265,"role":41,"phone":266,"phoneExt":33,"email":267},"Zhouqing Huang","+86-577-55578061","susiehzq@126.com",{"facility":37,"status":269,"city":48,"state":33,"zip":270,"country":50,"countryCode":51,"cosmosGeoPoint":271,"geoPoint":273,"contacts":274},"NOT_YET_RECRUITING","100034",{"type":53,"coordinates":272},[55,56],{"lat":56,"lon":55},[275],{"name":36,"role":41,"phone":42,"phoneExt":33,"email":43},{"type":277,"investigatorFullName":33,"investigatorTitle":33,"investigatorAffiliation":33,"oldNameTitle":33,"oldOrganization":33},"SPONSOR","100559771","phase-3-a-study-on-efficacy-and-safety-of-hst101-in-chinese-patients-with-hypercholesterolemia-100559771",false,"NCT06568471","A Study on Efficacy and Safety of HST101 in Chinese Patients with Hypercholesterolemia","A Randomized, Double-blind, Placebo-controlled Phase 3 Clinical Study to Evaluate the Efficacy and Safety of HST101 in Chinese Patients with Hypercholesterolemia","Inclusion Criteria:\n\n* Provision of written and signed informed consent form prior to any study-specific procedure;\n* Male or female participants ≥18 years of age at the screening visit;\n* Body weight ≥ 40 kg and body mass index (BMI) ≥18 and ≤35 kg\u002Fm2;\n* On a stable diet and lipid-lowering oral drugs (such as statins, ezetimibe or Hybutimibe, omega-3 compounds, fenofibrate, nicotinic acid, etc.) for at least 4 weeks prior to the first drug administration\n* LDL-C≥1.8 mmol\u002FL (70 mg\u002FdL) and TG≤4.52 mmol\u002FL (400 mg\u002FdL) at screening for ASCVD patients or those at very (ultra)-high risk for ASCVD, including patients with HeFH; LDL-C ≥ 2.6 mmol\u002FL (100 mg\u002FdL) and TG ≤ 4.52 mmol\u002FL (400 mg\u002FdL) at screening for patients at high-risk for ASCVD including patients with HeFH;\n* Patients on a PCSK9 mAb at a dose of 75 mg, 140 mg, or 150 mg Q2W must undergo a washout period of ≥6 weeks after the last dose; for those on 300 mg or 420 mg Q4W, the washout period is ≥10 weeks following last dose;\n* Female of childbearing potential must have a negative pregnancy test at the last screening visit and consent to use highly effective contraceptives during the trial and 3 months after the last dose of investigational drug.\n\nExclusion Criteria:\n\n* Documented history of homozygous familial hypercholesterolemia (HoFH);\n* Estimated glomerular filtration rate (eGFR)\\\u003C30 mL\u002Fmin\u002F1.73m2;\n* Active liver disease or hepatic dysfunction, history of liver transplant, and\u002For ALT or AST \\>2.5 × ULN at screening;\n* Poorly controlled thyroid disorder including hypothyroidism or hyperthyroidism;\n* Poorly controlled Type 1 or Type 2 diabetes mellitus defined as fasting blood glucose ≥11.0 mmol\u002FL (200 mg\u002FdL) and glycosylated hemoglobin (HbA1c) ≥ 9%;\n* Serious arrhythmia, MI, unstable angina pectoris, PCI, CABG, implantable cardioverter defibrillator, aortic valve surgery or stroke within 3 months prior to the first dose;\n* Planned cardiac surgery or revascularization during the study period;\n* New York Heart Association (NYHA) Class III-IV heart failure;\n* Pregnant or lactating women;\n* Poorly controlled hypertension (SBP≥160 mmHg or DBP≥100 mmHg in a sitting position)\n* Unexplained creatine kinase (CK) \\> 5 x ULN (retested once is needed if suspected to be related to excessive exercise or abnormal activity);\n* LDL apheresis or plasma exchange within 2 months prior to the first dose;\n* HIV, Treponema pallidum, or HCV antibody test positive, or HBV-DNA \\>ULN at screening;\n* History of prescription drug abuse, illicit drug use or alcohol abuse within 6 months prior to screening;\n* History of any major drug allergy, including allergy to protein biologics;\n* Participate another clinical trial within 30 days or less than 5 half-lifes (drug) before screening, whichever is longer","ALL","18 Years",{"count":288,"type":289},210,"ESTIMATED","INTERVENTIONAL",[292],"PHASE3","This randomized study is to assess LDL-C reductions at Week 12 with monthly (Q4W \\[≤31 days\\]) dosing of HST101 (lerodalcibep) 300 mg administered subcutaneously (SC) compared to placebo in patients with atherosclerotic cardiovascular disease (ASCVD) or very-high\u002Fhigh risk for ASCVD including Heterozygous familial hypercholesterolemia (HeFH) on a stable diet and oral LDL-C lowering drug therapy, followed by 36-week open-label treatment with subsequent 4-week follow-up for total 52-week long-term safety and efficacy evaluation.",[295,296,297,298,299,300,301],"Hypercholesterolemia","Dyslipidemias","Primary Hypercholesterolemia","Heterozygous Familial Hypercholesterolemia","Hyperlipidemia; Mixed","Metabolic Disease","ASCVD",[24,23,303],"LDL-C","2025-02-04",{"date":306,"type":307},"2025-02-06","ACTUAL",{"date":309,"type":307},"2024-11-16",{"date":311,"type":289},"2026-05",{"name":5,"class":6},18]